Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Invivyd ( (IVVD) ) has shared an update.
On August 20, 2025, Invivyd, Inc. entered into an underwriting agreement with Cantor Fitzgerald & Co. for a public offering of its common stock and pre-funded warrants, raising approximately $53.5 million. The proceeds will support the development of the VYD2311 clinical program, research on respiratory syncytial virus and measles, and efforts related to monoclonal antibody therapy for Long COVID, among other corporate purposes.
The most recent analyst rating on (IVVD) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Invivyd stock, see the IVVD Stock Forecast page.
Spark’s Take on IVVD Stock
According to Spark, TipRanks’ AI Analyst, IVVD is a Neutral.
Invivyd’s overall stock score reflects significant financial and technical weaknesses, marked by ongoing losses and bearish trends. While recent corporate developments offer a glimpse of potential strategic improvement, these are overshadowed by the current financial instability and weak market sentiment.
To see Spark’s full report on IVVD stock, click here.
More about Invivyd
Invivyd, Inc. is a biopharmaceutical company focused on providing protection against serious viral infectious diseases, starting with SARS-CoV-2. The company utilizes a proprietary technology platform to develop and adapt antibodies, and received emergency use authorization from the U.S. FDA for a monoclonal antibody in its pipeline in March 2024.
Average Trading Volume: 1,285,711
Technical Sentiment Signal: Sell
Current Market Cap: $68.6M
See more data about IVVD stock on TipRanks’ Stock Analysis page.